The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Kyowa Kirin Snares Japan Rights to BridgeBio’s Skeletal Dysplasias Drug
Kyowa Kirin has acquired the exclusive rights for BridgeBio Pharma’s investigational drug infigratinib in Japan for the treatment of skeletal dysplasias, the two companies said on February 7. The US biotech’s subsidiary QED Therapeutics has signed a deal to grant…
To read the full story
Related Article
- Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia
November 25, 2025
BUSINESS
- Generic Makers Positive on New AG Pricing, Cite Gains in Productivity and Predictability
January 8, 2026
- Bayer, University of Tsukuba Hospital Tie Up for Early Heart Failure Detection
January 8, 2026
- Envudeucitinib Hits PIII Goals in Psoriasis, JNDA Planned for 2027: Kaken
January 8, 2026
- Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…